Scientific deep-dive

ESG Results and Before-and-After: The Realistic Weight-Loss Timeline

What to realistically expect from ESG: fast early loss reaching ~13.6% total body weight loss at one year, pooling to 15-17% and holding near 16% at five years, with 77% of patients responding. The timeline, what before-and-after reflects, why results vary, and vs GLP-1s.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·8 citations

If you are looking at endoscopic sleeve gastroplasty (ESG) and searching “ESG before and after,” the honest question underneath is: what will actually happen to my weight, and when? Here is the realistic answer, from the trials. Weight loss is fast in the early months, reaches about 13.6% total body weight loss (TBWL) at one year in the pivotal MERIT randomized trial[1], pools to roughly 15–17% TBWL across studies[2], and holds near 16% at five years[3] — this is real fat loss that persists, not a water-weight blip that bounces back. About 77% of ESG patients reached at least 25% excess weight loss in MERIT (the responder threshold), versus 12% of controls[1]. Those numbers put ESG roughly on par with semaglutide (STEP-1: −14.9%[6]) and below tirzepatide (SURMOUNT-1: −20.9%[7]). But the “after” photo is not automatic: results vary by person, they depend heavily on sustained behavior change, and regain is possible if the eating changes lapse. This article walks the timeline month by month, explains what a real before-and-after reflects, why results differ, and how combining ESG with a GLP-1 shapes the trajectory.

The honest summary

  • Expect fast early loss, then a slower climb to a plateau. Pooled data show about 15.1% TBWL at 6 months, 16.5% at 12 months, and 17.2% at 18–24 months (Hedjoudje 2020[2]) — most of the drop happens in the first few months, then the curve flattens.
  • The one-year headline is ~13.6% TBWL. In the MERIT randomized trial, ESG produced 13.6% TBWL at 52 weeks versus 0.8% for lifestyle alone[1]. That is roughly on par with semaglutide[6] and below tirzepatide[7].
  • Most patients are responders. About 77% reached at least 25% excess weight loss in MERIT, versus 12% of controls[1] — so a meaningful “after” is the common outcome, not the exception.
  • The result is durable to about 5 years. A 216-patient cohort held 15.9% TBWL at 5 years[3], and MERIT showed 68% still maintaining ≥25% excess weight loss at 2 years[1]. The before-and-after doesn't evaporate the way a 6-month balloon's does[8].
  • The loss is reproducible, not a one-clinic fluke. Large international multicenter series (Sartoretto 2018[4]; Barrichello 2019[5]) confirmed similar results across many centers and operators — so your realistic expectation isn't built on a single pioneering endoscopist.
  • Results vary, and behavior decides how much. Starting weight, adherence to the post-procedure diet, activity, and follow-up all move the number. ESG restricts the stomach; it does not do the eating for you.
  • Regain is possible without sustained change — and a GLP-1 can help. ESG plus liraglutide beat ESG alone in a randomized study[1] context of combination care; pairing procedure and medication is increasingly how obesity is treated.

The ESG weight-loss timeline: what to expect, month by month

The most useful thing a before-and-after can't show you is the shape of the curve — how the loss actually accrues over time. Pooling the randomized and cohort evidence, the trajectory is consistent:

  • Weeks 1–4 (the adjustment phase). The stomach is freshly sutured into a narrow tube; portions are tiny, and a few days of abdominal discomfort and nausea are expected and settle. Early weight loss is often rapid as intake drops sharply.
  • Months 1–3 (fastest loss). This is where the steepest part of the curve happens. Restriction plus delayed gastric emptying means you feel full on much less, and the scale moves quickly.
  • Months 3–6 (~15% TBWL). The pace slows but continues; pooled data put ESG around 15.1% TBWL at 6 months[2]. Habits formed here matter enormously for what sticks.
  • Month 12 (~13.6–16.5% TBWL). The one-year mark — 13.6% in the MERIT RCT[1] and 16.5% in pooled analysis[2]. Most of the total loss is now banked and the curve is near its plateau.
  • Months 18–24 (~17% TBWL, the peak). Pooled TBWL edges up to about 17.2%[2], and roughly 68% of MERIT patients still hold ≥25% excess weight loss at 2 years[1].
  • Year 5 (~16% TBWL, holding). The five-year cohort maintained 15.9% TBWL[3] — the “after” is a durable one, provided the behavior change holds.
ESG weight-loss timeline (approximate total body weight loss over time)
Time pointApprox. TBWLEvidence
6 months~15.1%Hedjoudje pooled[2]
12 months~13.6-16.5%MERIT[1], Hedjoudje[2]
18-24 months~17.2% (peak)Hedjoudje pooled[2]
5 years~15.9% (holding)Sharaiha 5-year cohort[3]

What a real ESG “before and after” actually reflects

A credible before-and-after is a picture of genuine fat loss that persisted, not a transient effect. Three things are worth understanding about what you are looking at:

  • It is real weight loss, not water. ESG works by restriction (you feel full on far less food) and delayed gastric emptying (fullness lasts longer), which reduces caloric intake over months. The result is loss of body fat that shows up in TBWL, waist, and metabolic markers — MERIT documented improvements in type 2 diabetes, hypertension, and metabolic-syndrome markers alongside the weight change[1].
  • It reflects a plateau, not a peak that will vanish. Unlike a gastric balloon, whose loss peaks at 6 months and partly reverses after the device is removed[8], ESG's suture-based restriction persists, so the 1-to-5-year “after” tends to hold[1][3].
  • It is a responder's result, and most people respond. With 77% reaching ≥25% excess weight loss in MERIT[1], a visible before-and-after is the typical outcome — but not universal, which is exactly why results vary.

The responder rate: how likely is a meaningful result?

The single most reassuring number for someone weighing ESG is the responder rate. In MERIT, 77% of ESG patients reached at least 25% excess weight loss at one year, versus just 12% of the lifestyle-only controls, and mean excess weight loss was 49.2% for ESG versus 3.2% for control[1]. In plain terms: roughly three in four people get a clinically meaningful result, and it is dramatically more than they would achieve with lifestyle changes alone. That is a far higher hit rate than most people expect from a non-surgical procedure — and it is backed by a randomized trial, not just testimonials.

Why results vary from person to person

The trials report averages; your “after” is an individual outcome. The main levers that move it:

  • Adherence to the post-procedure plan. ESG shrinks capacity, but the eating pattern you build in the first 6 months — portion discipline, protein, avoiding grazing on soft high-calorie foods — is the biggest determinant of how much you lose and keep.
  • Starting weight and body composition. TBWL and excess-weight-loss percentages behave differently depending on where you start; the same procedure yields different absolute pounds.
  • Physical activity and muscle preservation. Activity supports the loss and protects lean mass, improving both the number and the body-composition quality of the result.
  • Follow-up and support. The best outcomes come from programs that pair ESG with structured dietitian and behavioral follow-up — the reproducible multicenter results were achieved within such programs[4][5].
  • Whether medication is added. Combining ESG with a GLP-1 shifts the trajectory upward (see below).

ESG results vs GLP-1 results, for context

Most people comparing an “after” are really asking how ESG stacks up against a GLP-1. No head-to-head trial exists, so these are cross-trial numbers — directional, not a contest — but the pattern is clear.

Approximate total body weight loss by intervention (cross-trial, not head-to-head)
InterventionTypical TBWLDurabilityKey evidence
Endoscopic sleeve gastroplasty (ESG)~13.6-17%Durable to ~5 yearsMERIT[1], Hedjoudje[2], Sharaiha[3]
Semaglutide 2.4 mg (Wegovy)~14.9%Sustained while takingSTEP-1[6]
Tirzepatide (Zepbound)~20.9%Sustained while takingSURMOUNT-1[7]
Gastric balloon (6-month device)~7-15%6 months, then regain commonASGE pooled Orbera[8]
Sleeve gastrectomy / gastric bypass~25-30%Durable, permanent anatomyBariatric surgery trials
  • ESG's before-and-after is in semaglutide's league and below tirzepatide's[1][6][7] — a similar destination reached by a very different route.
  • The structural difference shapes the “after” over time. ESG is a one-time procedure whose restriction persists; a GLP-1's loss tends to reverse if you stop. ESG's result holds without an ongoing prescription, though behavior still matters.
  • They are not either/or. Adding a GLP-1 to ESG produced more weight loss than ESG alone in a randomized combination study[1] framing — a “procedure plus medication” approach that can push the after further.
  • ESG's result is far more durable than a balloon's. A balloon peaks at 6 months and partly reverses[8]; ESG holds near 16% at 5 years[3].

For the focused procedure-versus-drug comparison, see ESG vs GLP-1 (semaglutide and tirzepatide).

Prefer a GLP-1, or want to add one to your ESG result? Top vetted providers

Prefer a GLP-1, or want to add one to your ESG result? Top vetted providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

No insurance needed · HSA/FSA eligible · vetted by our editors

7.3

altRX

The only platform offering all four brand-name GLP-1s plus compounded

Starting price: $149/mo

Get started →Read review altRX →
7.7

Synergy Rx

Broadest drug catalog in the Lion MD white-label cluster

Starting price: $199/mo

Get started →Read review Synergy Rx →
8.1

RxSpan MD

Physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

Starting price: $249/mo

Get started →Read review RxSpan MD →
7.4

Luvo Health

Compounded and brand GLP-1s, oral tablets and peptides on one price list

Starting price: $249/mo

Get started →Read review Luvo Health →
8.0

Strut Health

Oral-lozenge compounded GLP-1 access

Starting price: $99/mo

Get started →Read review Strut Health →

Regain: the honest caveat behind every “after”

ESG's five-year durability is a real strength — but it is not automatic. The suture-based restriction can loosen over time, and, more importantly, ESG does not replace the behavior change that keeps weight off. Some regain is common if the eating pattern reverts, particularly grazing on soft, calorie-dense foods that pass easily through a restricted stomach. The way to protect a before-and-after:

  • Treat the first 6 months as the foundation. The habits you lock in while restriction is strongest are what carry the result to year 5[3].
  • Keep the follow-up. Ongoing dietitian and behavioral support is part of how the durable, reproducible results were achieved[4][5].
  • Consider adding a GLP-1 if the loss stalls or regain starts. Combination care beat ESG alone in a randomized setting[1] and mirrors modern obesity treatment.
  • Know the future options stay open. Because ESG places sutures rather than removing tissue, it can be revised, and a surgical sleeve or bypass remains available later — see is ESG reversible?

Bottom line

  • Expect fast early loss flattening to about 13.6% TBWL at one year[1], pooling to 15–17%[2] and holding near 16% at five years[3] — real, durable fat loss, not a water-weight blip.
  • About 77% of patients are responders (≥25% excess weight loss in MERIT[1]), so a meaningful before-and-after is the common outcome, and the results are reproducible across many centers[4][5].
  • ESG's “after” is roughly on par with semaglutide[6], below tirzepatide[7], and far more durable than a 6-month balloon[8].
  • Results vary with starting weight, adherence, activity, and follow-up — ESG restricts the stomach, it does not do the eating for you.
  • Regain is possible without sustained change; locking in habits in the first 6 months, keeping follow-up, and optionally adding a GLP-1 protect the result.

Frequently Asked Questions

Expect fast loss early, then a slower climb to a plateau. Pooled data show about 15% total body weight loss by 6 months, rising to roughly 16-17% by 12-24 months (PMID 31442601), and the MERIT randomized trial reported 13.6% at one year (PMID 35908555). Most of the drop happens in the first few months while restriction is strongest. A five-year cohort held near 15.9% (PMID 33011292), so the loss is durable if behavior change holds.
Genuine, persistent fat loss - not water weight. ESG works by restriction and delayed gastric emptying, which lowers calorie intake over months, producing loss that shows up in weight, waist, and metabolic markers (MERIT documented diabetes, blood-pressure, and metabolic-syndrome improvements; PMID 35908555). Unlike a gastric balloon, whose loss peaks at 6 months and partly reverses after removal (PMID 26232362), ESG's suture-based restriction persists, so the 1-to-5-year after tends to hold.
Most do. In the MERIT randomized trial, about 77% of ESG patients reached at least 25% excess weight loss at one year, versus 12% of lifestyle-only controls, with mean excess weight loss of 49.2% versus 3.2% (PMID 35908555). Roughly three in four people get a clinically meaningful result - a much higher responder rate than most expect from a non-surgical procedure, and one backed by a randomized trial rather than testimonials.
There is no head-to-head trial, so this is cross-trial. ESG's roughly 13.6-17% total body weight loss (PMID 35908555, PMID 31442601) is similar to semaglutide's ~14.9% (PMID 33567185) and below tirzepatide's ~20.9% (PMID 35658024). The difference is structural: ESG is a one-time procedure whose restriction persists, whereas a GLP-1's loss tends to reverse if you stop. They can also be combined, which pushes the result further.
Some regain is possible if the eating pattern reverts, because ESG restricts the stomach but does not replace behavior change - grazing on soft, calorie-dense foods can undo results. That said, the loss is durable on average, holding near 16% at five years (PMID 33011292). The best protection is locking in habits during the first 6 months when restriction is strongest, keeping dietitian and behavioral follow-up, and, if loss stalls or regain begins, considering the addition of a GLP-1.
The durability data extend to about five years. A 216-patient cohort maintained roughly 15.9% total body weight loss at 5 years (PMID 33011292), and the MERIT randomized trial showed about 68% of patients still holding at least 25% excess weight loss at 2 years (PMID 35908555). Because ESG uses sutures to reshape the stomach rather than removing tissue, the restriction persists over time, though it can loosen and results depend on sustained eating changes. Published data beyond five years are limited, so longer-term durability is still being studied. Unlike a gastric balloon, whose loss peaks at 6 months and partly reverses after removal (PMID 26232362), ESG's after tends to hold.
There is no fixed timeline, and 100 pounds is more than the average ESG result for most starting weights. ESG produces roughly 13.6-17% total body weight loss (MERIT, PMID 35908555; pooled data, PMID 31442601), so 100 pounds would correspond to that percentage only for someone starting around 600-730 pounds; for most patients the absolute loss is smaller. When large losses do occur, most of the drop happens in the first 3-6 months, with the curve flattening toward a plateau by 12-24 months. Combining ESG with a GLP-1 or with structured diet and activity can increase the total. Individual results vary widely, and a realistic target should be set with your bariatric specialist.
The main advantages: ESG is incisionless and organ-sparing (sutures rather than cutting), typically done as an outpatient procedure with faster recovery than surgery, produces durable loss to about 5 years (roughly 16%; PMID 33011292), and keeps future options open since it can be revised or converted to surgery. The trade-offs: the average weight loss (about 13.6-17%; PMID 35908555, PMID 31442601) is less than surgical sleeve or bypass, results depend heavily on sustained behavior change, some regain is possible if eating reverts, it is often not covered by insurance, and there are procedure-related risks such as bleeding, nausea, and rarely more serious complications. Whether ESG is the right fit should be assessed by a qualified bariatric endoscopist.
The suturing reduces stomach capacity so you feel full on much less, but ESG does not make overeating impossible, and grazing on soft, calorie-dense foods that pass easily through a restricted stomach is the most common way results are undone. Consistently eating past fullness can also gradually stretch capacity over time. This is why the eating pattern built in the first 6 months -- portion control, prioritizing protein, and avoiding continuous snacking -- is the biggest determinant of how much weight you lose and keep. If loss stalls or regain begins, dietitian and behavioral follow-up, and sometimes adding a GLP-1, help protect the result.

References

  1. 1.Abu Dayyeh BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, Thompson CC, et al.; MERIT Study Group. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial. Lancet. 2022. PMID: 35908555.
  2. 2.Hedjoudje A, Abu Dayyeh BK, Cheskin LJ, Adam A, Neto MG, et al. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020. PMID: 31442601.
  3. 3.Sharaiha RZ, Hajifathalian K, Kumar R, Saumoy M, Dawod Q, et al. Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. Clin Gastroenterol Hepatol. 2021. PMID: 33011292.
  4. 4.Sartoretto A, Sui Z, Hill C, Dunlap M, Rivera AR, et al. Endoscopic Sleeve Gastroplasty (ESG) Is a Reproducible and Effective Endoscopic Bariatric Therapy Suitable for Widespread Clinical Adoption: a Large, International Multicenter Study. Obes Surg. 2018. PMID: 29450845.
  5. 5.Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, Jirapinyo P, Hoff AC, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc. 2019. PMID: 31228432.
  6. 6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al.; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  7. 7.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
  8. 8.Abu Dayyeh BK, Kumar N, Edmundowicz SA, Jonnalagadda S, Larsen M, et al.; ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015. PMID: 26232362.

Retatrutide Before and After: What TRIUMPH-1 Actually Showed

TRIUMPH-1 (n=2,339) reported 28.3% mean weight loss at 80 weeks on retatrutide 12 mg and 30.3% at 104 weeks in the BMI 35+ extension. Honest framing of transformation magnitude, dose-response, and how real-world results typically run 60-80% of pivotal-trial TBWL.

12 min read

ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence

A one-time incisionless procedure or a weekly injection for life? ESG produced ~13.6-16% weight loss vs ~14.9% for semaglutide and ~20.9% for tirzepatide, but no head-to-head trial exists. Efficacy, durability, cost over time, risk, and the combination that beats either alone.

12 min read

Endoscopic (Non-Surgical) Weight-Loss Options: ESG, Balloon, and GLP-1 Compared

Endoscopic bariatric therapy sits between GLP-1 drugs and surgery. ESG produced 13.6% weight loss in the MERIT trial and holds near 16% at 5 years; the intragastric balloon gives ~7-15% over 6 months. How the incisionless options compare to each other, to GLP-1s, and to surgery.

12 min read

Endoscopic Sleeve Gastroplasty (ESG): The Evidence vs GLP-1s and Surgery

Endoscopic sleeve gastroplasty (ESG) is an incisionless stomach-tightening procedure that produced 13.6% weight loss in the MERIT randomized trial - on par with semaglutide, below tirzepatide and surgery. The honest evidence on efficacy, safety, cost, reversibility, and how it compares to a GLP-1.

12 min read

ESG vs Gastric Sleeve: Incisionless Stitching vs Surgical Sleeve Gastrectomy

Endoscopic sleeve gastroplasty (ESG) and surgical sleeve gastrectomy both make a stomach tube, but ESG is incisionless and reversible (~13.6% weight loss) while the surgical sleeve removes most of the stomach for ~25-30%. The honest evidence on efficacy, safety, reversibility, cost, and both vs a GLP-1.

11 min read

How Much Does ESG Cost? Endoscopic Sleeve Gastroplasty Price vs a GLP-1

Endoscopic sleeve gastroplasty (ESG) typically costs about $8,000-$20,000 in the US, usually paid out of pocket because most insurers call it investigational. The honest value math: one large one-time cost with no drug bill vs a GLP-1 you pay for every month - plus what's included, financing, and cost vs surgery.

9 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

6.2

Wellorithm

Compounded GLP-1 access with oral tablet options across 49 states

7.1

AgelessRx

Longevity-focused GLP-1 care

8.0

Sesame Care

Brand-name GLP-1s at cash prices, no compounding